Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

From chemotherapy to reprogrammed cells: how leukemia treatment changed

Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

For most of the twentieth century leukemia treatment meant poisoning every fast-dividing cell in the body and hoping the cancer died first. It worked often enough to be worth the cost, and the cost was brutal.

Then the Philadelphia chromosome gave drug designers an exact target, and the field changed shape.

Related pages: Leukemia (blood cancer)

The bottom line

What we know
  • Targeted drugs block a specific mutated protein rather than all dividing cells.
  • BCL-2 and BTK inhibitors work by restoring cell death or cutting survival signals.
  • CAR-T therapy re-engineers a person's own T-cells to recognize and kill leukemia cells.
  • Stem cell transplant replaces the marrow and supplies a donor immune system that patrols for leukemia.
What is still open
  • Whether some people on targeted drugs can stop them permanently.
  • How to prevent leukemia cells escaping CAR-T by losing the target molecule.

The story, step by step

  1. 1. Chemotherapy ()
  2. 2. Kinase inhibitors ()
  3. 3. Restoring cell death ()
  4. 4. Immunotherapy ()
  5. 5. Transplant ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

Still the backbone, and still blunt

Review of many studies

What happens

Conventional chemotherapy attacks cells that divide rapidly. Leukemia cells qualify, and so do several normal tissues.

What the research shows

  • It remains the foundation of treatment for ALL and for intensive AML therapy, and it cures a large majority of children with ALL.
  • Marrow, hair follicles and the lining of the gut divide quickly too, which is the source of most side effects.
  • ALL treatment runs in phases over two to three years, including maintenance, because stopping early leads to relapse.
  • Drugs are also given into the spinal fluid, since standard chemotherapy does not cross into the nervous system well.

Why it matters

The newer drugs get the attention, but chemotherapy is what produced the first cures, and for childhood ALL it still does most of the work.

What's still uncertain

  • Late effects of childhood treatment, on the heart, fertility and second cancers, are a major focus of survivorship care.

Read more

Next: Kinase inhibitors

Part 2 of 5

A key cut for one lock

Lab or animal study

What happens

Once BCR-ABL1 was identified as a single always-on enzyme, it became possible to design a molecule that plugs it.

What the research shows

  • Imatinib fits into the pocket where the mutant enzyme binds its fuel, ATP, and switches the growth signal off.
  • Approved in 2001, it turned CML from a disease measured in years into one most people live with long-term.
  • Later generations, including dasatinib, nilotinib, bosutinib, ponatinib and asciminib, handle resistance mutations that defeat imatinib.
  • The same approach is used elsewhere: FLT3 inhibitors in AML, and IDH1 and IDH2 inhibitors for those mutations.

Why it matters

This is why the genetic panel matters. The drug is chosen for the mutation, and without the mutation the drug does nothing.

What's still uncertain

  • Resistance can still emerge, and some mutations remain difficult to target.

Read more

Next: Restoring cell death

Part 3 of 5

Venetoclax and the BTK inhibitors

Lab or animal study

What happens

Some leukemia cells survive not by dividing faster but by refusing to die.

What the research shows

  • BCL-2 is a protein that blocks apoptosis, the cell's self-destruct program. Leukemic cells often overproduce it.
  • Venetoclax blocks BCL-2 and lets the self-destruct program run again. It is used in CLL and, with azacitidine, in AML for people who cannot tolerate intensive chemotherapy.
  • BTK inhibitors, including ibrutinib, acalabrutinib and zanubrutinib, cut the survival signals that CLL cells depend on.
  • Because venetoclax can kill cells very rapidly, it is started at a low dose and stepped up, to avoid tumor lysis syndrome, in which the contents of dying cells overwhelm the kidneys.

Why it matters

These drugs moved CLL away from chemotherapy almost entirely in the space of a decade.

What's still uncertain

  • Long-term outcomes for the newest combinations are still accumulating, and resistance mechanisms are being catalogued.

Read more

Next: Immunotherapy

Part 4 of 5

Pointing the immune system at the right cell

Lab or animal study

What happens

Rather than killing leukemia directly, these approaches recruit the patient's own T-cells.

What the research shows

  • Blinatumomab is a bispecific antibody: one end grips a CD19 molecule on the leukemia cell, the other grips a T-cell, and holds them together until the T-cell kills.
  • CAR-T therapy takes a person's T-cells, adds a gene for a chimeric antigen receptor that recognizes CD19, grows them, and infuses them back.
  • CAR-T has produced remissions in B-cell ALL that had already relapsed after everything else, in children and in adults.
  • It carries serious risks: cytokine release syndrome, a severe inflammatory reaction, and neurological toxicity, both of which need intensive-care-level monitoring.
  • Leukemia can escape by losing the CD19 molecule the receptor recognizes, and work on receptors targeting more than one molecule is ongoing.

Why it matters

A treatment made from the patient's own cells, for one patient, was science fiction when many people now living with leukemia were diagnosed.

What's still uncertain

  • Access is limited to specialist centres, and the cost is extremely high.

Read more

Next: Transplant

Part 5 of 5

Replacing the factory, and borrowing an immune system

Review of many studies

What happens

Allogeneic stem cell transplant remains the most intensive option and, for some people, the only curative one.

What the research shows

  • High-dose chemotherapy, sometimes with radiation, clears the diseased marrow, and donor stem cells rebuild it.
  • The donor immune system also patrols for remaining leukemia cells, an effect called graft-versus-leukemia, which is a major part of why it works.
  • The same donor immunity can attack the recipient's own tissue, which is graft-versus-host disease, the central risk of the procedure.
  • Reduced-intensity conditioning has made transplant possible for older adults who could not have tolerated the older regimens.
  • Whether to transplant depends on subtype, genetics, response to first treatment, age and fitness, and it is one of the hardest decisions in haematology.

Why it matters

Transplant is not a last resort for everyone, nor a routine step. For some genetic subtypes it is recommended in first remission, before any relapse.

What's still uncertain

  • Predicting who will get severe graft-versus-host disease remains imprecise.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.